133 related articles for article (PubMed ID: 15529715)
1. [Minor rate of side-effects makes it possible. Coxibs accrue new indications].
MMW Fortschr Med; 2004 Aug; 146(31-32):49. PubMed ID: 15529715
[No Abstract] [Full Text] [Related]
2. [Is there a future for COX-2 inhibitors?].
Yodfat Y
Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
[TBL] [Abstract][Full Text] [Related]
3. What happened to the coxibs on the way to the cardiologist?
Alberts DS; Potter JD; Martinez ME; Hess LM; Stopeck A; Lance P
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):555-6. PubMed ID: 15767326
[No Abstract] [Full Text] [Related]
4. The safety of the perioperative administration of cyclooxygenase-2 inhibitors for post-surgical pain.
Reuben SS
Acta Anaesthesiol Scand; 2005 Mar; 49(3):424; author reply 425. PubMed ID: 15752415
[No Abstract] [Full Text] [Related]
5. Comment on efficacy of rofecoxib and nimesulide in controlling post-extraction pain in oral surgery: a randomised comparative study.
Villa G
Curr Med Res Opin; 2004 Apr; 20(4):573-4; author reply 574. PubMed ID: 15119995
[No Abstract] [Full Text] [Related]
6. [Really only Vioxx?].
Heinzl S
Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
[No Abstract] [Full Text] [Related]
7. [General practice study of therapy of acute pain. Patients prefer cox-2 inhibitors].
MMW Fortschr Med; 2004 May; 146(21):61. PubMed ID: 15373091
[No Abstract] [Full Text] [Related]
8. [Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)].
Kick A; Bertoli R; Moschovitis G; Caduff Janosa P; Cerny A
Med Klin (Munich); 2005 Apr; 100(4):213-6. PubMed ID: 15834531
[TBL] [Abstract][Full Text] [Related]
9. COX-2 inhibitor improves pain outcomes.
OR Manager; 2004 Jan; 20(1):21. PubMed ID: 14740474
[No Abstract] [Full Text] [Related]
10. COX-2 inhibitors and hypercoagulability.
Farkouh ME
Clin Adv Hematol Oncol; 2005 Jan; 3(1):35-6. PubMed ID: 16166966
[No Abstract] [Full Text] [Related]
11. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
Bijlsma JW
Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
[TBL] [Abstract][Full Text] [Related]
12. [The rise and fall of Vioxx: society, values and their choice].
Caspi D
Harefuah; 2004 Nov; 143(11):770-1. PubMed ID: 15603261
[No Abstract] [Full Text] [Related]
13. Balancing risks and benefits in pain medicine: wither Vioxx.
Gallagher RM
Pain Med; 2004 Dec; 5(4):329-30. PubMed ID: 15563316
[No Abstract] [Full Text] [Related]
14. Rofecoxib for osteoarthritis and pain.
Med Lett Drugs Ther; 1999 Jul; 41(1056):59-61. PubMed ID: 10436769
[No Abstract] [Full Text] [Related]
15. Vioxx doctors wooed by Merck are now its foes.
Tesoriero HW
Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
[No Abstract] [Full Text] [Related]
16. [VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases].
Jerie P
Cas Lek Cesk; 2005; 144(1):4. PubMed ID: 15789774
[No Abstract] [Full Text] [Related]
17. Intracranial hypertension induced by rofecoxib.
Jacob S; Rajabally YA
Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
[TBL] [Abstract][Full Text] [Related]
18. Myths and facts in the use of anti-inflammatory drugs.
Hunt RH; Lanas A; Stichtenoth DO; Scarpignato C
Ann Med; 2009; 41(6):423-37. PubMed ID: 19430988
[TBL] [Abstract][Full Text] [Related]
19. Health Canada lukewarm on Vioxx panel findings.
Murray S
CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502
[No Abstract] [Full Text] [Related]
20. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Couzin J
Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
